U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Multiple cutaneous leiomyomas(MCL; MCUL1; HLRCC; LRCC)

MedGen UID:
353771
Concept ID:
C1708350
Neoplastic Process
Synonyms: Cutaneous leiomyomata with uterine leiomyomata; Familial leiomyomatosis; Hereditary leiomyomatosis and renal cell cancer; Leiomyoma, hereditary multiple, of skin; Leiomyoma, multiple cutaneous; Multiple cutaneous and uterine leiomyomata; MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATA 1, WITH OR WITHOUT RENAL CELL CARCINOMA; Multiple cutaneous and uterine leiomyomatosis; Reed syndrome
SNOMED CT: HLRCC - hereditary leiomyomatosis and renal cell cancer (1162799008); Familial leiomyomatosis with renal carcinoma (1162799008); Hereditary leiomyomatosis with renal carcinoma (1162799008); Familial leiomyomatosis and renal cell cancer (1162799008); Hereditary leiomyomatosis and renal cell carcinoma (1162799008); Hereditary leiomyomatosis and renal cell cancer (1162799008)
Modes of inheritance:
Autosomal dominant inheritance
MedGen UID:
141047
Concept ID:
C0443147
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele.
 
Gene (location): FH (1q43)
 
HPO: HP:0007437
Monarch Initiative: MONDO:0007888
OMIM®: 150800
Orphanet: ORPHA523

Disease characteristics

Excerpted from the GeneReview: FH Tumor Predisposition Syndrome
FH tumor predisposition syndrome is characterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), and/or renal tumors. Pheochromocytoma and paraganglioma have also been described in a small number of families. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 30 years, increasing in size and number with age. Uterine leiomyomata tend to be numerous and large; age at diagnosis ranges from 18 to 53 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors are usually unilateral, solitary, and aggressive. They are associated with poor survival due to clinical aggressiveness and propensity to metastasize despite small primary tumor size. The median age of detection is approximately age 40 years. [from GeneReviews]
Authors:
Junne Kamihara  |  Kris Ann Schultz  |  Huma Q Rana   view full author information

Additional descriptions

From OMIM
Hereditary leiomyomatosis and renal cell cancer is an autosomal dominant tumor predisposition syndrome characterized by the variable development of 3 tumors: cutaneous piloleiomyomata that develop in essentially all patients by age 40 years; leiomyomata (fibroids) of the uterus, and rarely leiomyosarcomas, at a mean age of 30 years (range, 18 to 52 years); and type 2 papillary renal cell carcinoma at a mean age of 46 years (range, 17 to 75 years), which occurs in about 20% of patients. Type 2 papillary renal cell carcinoma is a pathologic subtype characterized by large tumor cells with eosinophilic cytoplasm and pseudostratified nuclei; it shows an aggressive clinical course. Some patients with FH mutations may develop collecting duct renal cell carcinoma. The main focus of management in HLRCC is prevention of disease and death due to renal cancer (summary by Gardie et al., 2011; Smit et al., 2011; and Lehtonen, 2011). For a general discussion of papillary renal cell carcinoma, see RCCP1 (605074).  http://www.omim.org/entry/150800
From MedlinePlus Genetics
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign tumors containing smooth muscle tissue (leiomyomas) in the skin and, in females, the uterus. This condition also increases the risk of kidney cancer.

In this disorder, growths on the skin (cutaneous leiomyomas) typically develop in the third decade of life. Most of these growths arise from the tiny muscles around the hair follicles that cause "goosebumps". They appear as bumps or nodules on the trunk, arms, legs, and occasionally on the face. Cutaneous leiomyomas may be the same color as the surrounding skin, or they may be darker. Some affected individuals have no cutaneous leiomyomas or only a few, but the growths tend to increase in size and number over time. Cutaneous leiomyomas are often more sensitive than the surrounding skin to cold or light touch, and may be painful.

Most women with HLRCC also develop uterine leiomyomas (fibroids). While uterine fibroids are very common in the general population, women with HLRCC tend to have numerous large fibroids that appear earlier than in the general population.

Approximately 10 percent to 16 percent of people with HLRCC develop a type of kidney cancer called renal cell cancer. The signs and symptoms of renal cell cancer may include lower back pain, blood in the urine, or a mass in the kidney that can be felt upon physical examination. Some people with renal cell cancer have no symptoms until the disease is advanced. People with HLRCC are commonly diagnosed with kidney cancer in their forties.

This disorder, especially if it appears in individuals or families without renal cell cancer, is also sometimes called multiple cutaneous leiomyomatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL).  https://medlineplus.gov/genetics/condition/hereditary-leiomyomatosis-and-renal-cell-cancer

Clinical features

From HPO
Renal cell carcinoma
MedGen UID:
766
Concept ID:
C0007134
Neoplastic Process
A type of carcinoma of the kidney with origin in the epithelium of the proximal convoluted renal tubule.
Uterine leiomyoma
MedGen UID:
21801
Concept ID:
C0042133
Neoplastic Process
Uterine leiomyoma (UL), commonly known as fibroids, are benign tumors of the uterine myometrium. They represent the most prevalent pelvic tumors in women and are found in more than 75% of women of reproductive age. Approximately 20 to 25% of women with UL exhibit symptoms including menorrhagia, infertility, pelvic pain, and a range of complications during pregnancy. UL are the leading cause for hysterectomy in the United States, accounting for 30% of all hysterectomies (summary by Eggert et al., 2012).
Uterine leiomyosarcoma
MedGen UID:
83679
Concept ID:
C0280631
Neoplastic Process
The presence of a leiomyosarcoma of the uterus.
Cutaneous leiomyoma
MedGen UID:
87533
Concept ID:
C0346064
Neoplastic Process
The presence of leiomyoma of the skin.
Cutaneous leiomyosarcoma
MedGen UID:
87534
Concept ID:
C0346067
Neoplastic Process
The presence of leiomyosarcoma of the skin.
Multiple cutaneous leiomyomas
MedGen UID:
353771
Concept ID:
C1708350
Neoplastic Process
FH tumor predisposition syndrome is characterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), and/or renal tumors. Pheochromocytoma and paraganglioma have also been described in a small number of families. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 30 years, increasing in size and number with age. Uterine leiomyomata tend to be numerous and large; age at diagnosis ranges from 18 to 53 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors are usually unilateral, solitary, and aggressive. They are associated with poor survival due to clinical aggressiveness and propensity to metastasize despite small primary tumor size. The median age of detection is approximately age 40 years.
Decreased fumarate hydratase activity
MedGen UID:
343007
Concept ID:
C1853903
Finding
An abnormality of Krebs cycle metabolism that is characterized by a decreased rate of fumarate hydratase activity.

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMultiple cutaneous leiomyomas

Conditions with this feature

Multiple cutaneous leiomyomas
MedGen UID:
353771
Concept ID:
C1708350
Neoplastic Process
FH tumor predisposition syndrome is characterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), and/or renal tumors. Pheochromocytoma and paraganglioma have also been described in a small number of families. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 30 years, increasing in size and number with age. Uterine leiomyomata tend to be numerous and large; age at diagnosis ranges from 18 to 53 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors are usually unilateral, solitary, and aggressive. They are associated with poor survival due to clinical aggressiveness and propensity to metastasize despite small primary tumor size. The median age of detection is approximately age 40 years.

Professional guidelines

PubMed

El-Zaatari Z, Divatia MK
Indian J Pathol Microbiol 2020 Feb;63(Supplement):S7-S17. doi: 10.4103/IJPM.IJPM_877_19. PMID: 32108620
Malik K, Patel P, Chen J, Khachemoune A
Am J Clin Dermatol 2015 Feb;16(1):35-46. doi: 10.1007/s40257-015-0112-1. PMID: 25605645

Recent clinical studies

Etiology

Bhola PT, Gilpin C, Smith A, Graham GE
Fam Cancer 2018 Oct;17(4):615-620. doi: 10.1007/s10689-018-0076-4. PMID: 29423582
Collgros H, Iglesias-Sancho M, Tribó-Boixareu MJ, Creus-Vila L, Umbert-Millet P, Salleras-Redonnet M
Actas Dermosifiliogr 2015 Mar;106(2):117-25. Epub 2014 Oct 14 doi: 10.1016/j.ad.2014.08.005. PMID: 25439147
Chan I, Wong T, Martinez-Mir A, Christiano AM, McGrath JA
Clin Exp Dermatol 2005 Jan;30(1):75-8. doi: 10.1111/j.1365-2230.2004.01675.x. PMID: 15663510
Cassetty CT
Dermatol Online J 2004 Nov 30;10(3):5. PMID: 15748575

Diagnosis

Ji X, Bi H, Dong A
Clin Nucl Med 2020 Oct;45(10):827-829. doi: 10.1097/RLU.0000000000003213. PMID: 32701814
Patel VM, Handler MZ, Schwartz RA, Lambert WC
J Am Acad Dermatol 2017 Jul;77(1):149-158. Epub 2017 Mar 14 doi: 10.1016/j.jaad.2017.01.023. PMID: 28314682
Buelow B, Cohen J, Nagymanyoki Z, Frizzell N, Joseph NM, McCalmont T, Garg K
Am J Surg Pathol 2016 Jul;40(7):982-8. doi: 10.1097/PAS.0000000000000626. PMID: 26945337
Collgros H, Iglesias-Sancho M, Tribó-Boixareu MJ, Creus-Vila L, Umbert-Millet P, Salleras-Redonnet M
Actas Dermosifiliogr 2015 Mar;106(2):117-25. Epub 2014 Oct 14 doi: 10.1016/j.ad.2014.08.005. PMID: 25439147
Fernández-Pugnaire MA, Delgado-Florencio V
Dermatology 1995;191(4):295-8. doi: 10.1159/000246578. PMID: 8573925

Therapy

Gravvanis A, Kakagia D, Papadopoulos S, Tsoutsos D
J Cutan Med Surg 2009 Mar-Apr;13(2):102-5. doi: 10.2310/7750.2008.07074. PMID: 19298779
Tiffee JC, Budnick SD
Oral Surg Oral Med Oral Pathol 1993 Dec;76(6):716-7. doi: 10.1016/0030-4220(93)90040-b. PMID: 8284075

Prognosis

Bhola PT, Gilpin C, Smith A, Graham GE
Fam Cancer 2018 Oct;17(4):615-620. doi: 10.1007/s10689-018-0076-4. PMID: 29423582
Buelow B, Cohen J, Nagymanyoki Z, Frizzell N, Joseph NM, McCalmont T, Garg K
Am J Surg Pathol 2016 Jul;40(7):982-8. doi: 10.1097/PAS.0000000000000626. PMID: 26945337
Yoshinaga Y, Nakai H, Hayashi R, Ito A, Kariya N, Ito M, Shimomura Y
J Dermatol 2016 Jan;43(1):85-91. Epub 2015 Jul 15 doi: 10.1111/1346-8138.13019. PMID: 26173633
Chan I, Wong T, Martinez-Mir A, Christiano AM, McGrath JA
Clin Exp Dermatol 2005 Jan;30(1):75-8. doi: 10.1111/j.1365-2230.2004.01675.x. PMID: 15663510

Clinical prediction guides

Bhola PT, Gilpin C, Smith A, Graham GE
Fam Cancer 2018 Oct;17(4):615-620. doi: 10.1007/s10689-018-0076-4. PMID: 29423582
Buelow B, Cohen J, Nagymanyoki Z, Frizzell N, Joseph NM, McCalmont T, Garg K
Am J Surg Pathol 2016 Jul;40(7):982-8. doi: 10.1097/PAS.0000000000000626. PMID: 26945337
Chan I, Wong T, Martinez-Mir A, Christiano AM, McGrath JA
Clin Exp Dermatol 2005 Jan;30(1):75-8. doi: 10.1111/j.1365-2230.2004.01675.x. PMID: 15663510
Garman ME, Blumberg MA, Ernst R, Raimer SS
Dermatology 2003;207(2):210-3. doi: 10.1159/000071802. PMID: 12920381
Fernández-Pugnaire MA, Delgado-Florencio V
Dermatology 1995;191(4):295-8. doi: 10.1159/000246578. PMID: 8573925

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...